EndoCell
Latest round
- Series A
Last raised
- May 2025
Total raised
- $24M
Investors
- 3
About EndoCell
Established in 2019 and based in Shanghai, China, EndoCell is a regenerative islet research and development company focuses on the in vitro regeneration technology of human tissues and organs. FounderXin Cheng is from the Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences. In April 2025, the first product pipeline, allogeneic human regenerative islet injection (E-islet 01), acquired IND clinical approval from the National Medical Products Administration. The company's main product line is regenerative pancreatic islet transplantation. It also provides in vitro reconstruction of human tissues and organs. The company generates revenue by providing in vitro reconstructed pancreatic islet tissue. The company will use the funds to conduct Phase I/II clinical trials of its allogeneic universal regenerated islet pipeline, accelerate strategic deployment, and develop new pipelines for the treatment of diabetes and liver disease.
Who invested in EndoCell
3 investors across 2 rounds
See all investors in EndoCell
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about EndoCell
Who invested in EndoCell?
EndoCell has 3 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has EndoCell raised?
EndoCell has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did EndoCell last raise money?
EndoCell's most recent round on record is a Series A, in May 2025.
What does EndoCell do?
Established in 2019 and based in Shanghai, China, EndoCell is a regenerative islet research and development company focuses on the in vitro regeneration technology of human tissues and organs.
Where is EndoCell headquartered?
EndoCell is headquartered in Shanghai, China.
Which VCs invest in companies like EndoCell?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at EndoCell's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like EndoCell? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.